Cited 1 times in
Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김진석 | - |
dc.date.accessioned | 2022-12-22T01:27:49Z | - |
dc.date.available | 2022-12-22T01:27:49Z | - |
dc.date.issued | 2022-02 | - |
dc.identifier.issn | 0147-0272 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191232 | - |
dc.description.abstract | Lenalidomide and low-dose dexamethasone (Rd) are a standard treatment for older adults with multiple myeloma (MM). Lenalidomide monotherapy has rarely been evaluated for newly diagnosed transplant-ineligible MM patients. This multicenter phase II trial evaluated a response-adapted strategy for elderly patients with newly diagnosed MM without high-risk features. Patients were administered single-agent lenalidomide for the first 21 days of two 28-day cycles. Patients with progressive disease received Rd. The primary endpoint was progression-free survival using the uniform response assessment from the International Myeloma Working Group . Of the 34 enrolled patients, 28 were included in the efficacy analysis. The overall response rate (ORR, ≥ partial response [PR]) to single-agent lenalidomide or lenalidomide plus prednisone was 64.3%. Ten patients received Rd after disease progression, with an Rd ORR of 70%. The ORR of response-adapted lenalidomide-based therapy was 75%. After the median follow-up of 35.6 months, the median progression-free survival was 33.5 months (95% confidence interval [CI], 16.9-50.2), and the median overall survival was 51.8 months (95% CI, 22.0-81.6). The most common adverse event was neutropenia (46.7%), and 17 patients (56.7%) experienced infection including pneumonia. Response-adapted lenalidomide-based therapy was feasible in newly diagnosed, transplant-ineligible MM patients without high-risk features. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Mosby | - |
dc.relation.isPartOf | CURRENT PROBLEMS IN CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lenalidomide* / adverse effects | - |
dc.subject.MESH | Multiple Myeloma* / diagnosis | - |
dc.subject.MESH | Multiple Myeloma* / drug therapy | - |
dc.subject.MESH | Progression-Free Survival | - |
dc.title | Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Kwai Han Yoo | - |
dc.contributor.googleauthor | Dok Hyun Yoon | - |
dc.contributor.googleauthor | Hye Jin Kang | - |
dc.contributor.googleauthor | Won Sik Lee | - |
dc.contributor.googleauthor | Kihyun Kim | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.contributor.googleauthor | Jeong-A Kim | - |
dc.contributor.googleauthor | Sung-Hyun Kim | - |
dc.contributor.googleauthor | Jae-Yong Kwak | - |
dc.contributor.googleauthor | Yang Soo Kim | - |
dc.contributor.googleauthor | Chang-Ki Min | - |
dc.contributor.googleauthor | Je-Jung Lee | - |
dc.contributor.googleauthor | Sung-Soo Yoon | - |
dc.contributor.googleauthor | Cheolwon Suh | - |
dc.contributor.googleauthor | Rachid Baz | - |
dc.contributor.googleauthor | Jae Hoon Lee | - |
dc.identifier.doi | 10.1016/j.currproblcancer.2021.100788 | - |
dc.contributor.localId | A01017 | - |
dc.relation.journalcode | J04344 | - |
dc.identifier.eissn | 1535-6345 | - |
dc.identifier.pmid | 34454742 | - |
dc.subject.keyword | Corticosteroids | - |
dc.subject.keyword | Lenalidomide | - |
dc.subject.keyword | Myeloma | - |
dc.subject.keyword | Older adults | - |
dc.subject.keyword | Response-adapted therapy | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | 김진석 | - |
dc.citation.volume | 46 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 100788 | - |
dc.identifier.bibliographicCitation | CURRENT PROBLEMS IN CANCER, Vol.46(1) : 100788, 2022-02 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.